Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12796417 | 0.96 | PPARG (0.37) | PPARGPPARDGPR119NR1I2OGA | |
| SCHEMBL13021438 | 0.87 | PPARG (0.39) | PPARGPPARDGPR119NR1I2OGA | |
| SCHEMBL1665706 | 0.87 | PPARG (0.42) | PPARGPPARDGPR119NR1I2OGA | |
| SCHEMBL13021436 | 0.83 | PPARG (0.43) | PPARGPPARDGPR119NR1I2OGA | |
| SCHEMBL9986408 | 0.82 | GPR119 (0.45) | GPR119NR1I2ALDH1A1TP53KDM4E | |
| SCHEMBL14491327 | 0.80 | PPARG (0.40) | PPARGPPARDGPR119NR1I2ALDH1A1 | |
| SCHEMBL1801158 | 0.80 | PDE10A (0.40) | PPARGPPARDGPR119NR1I2OGA | |
| SCHEMBL14491330 | 0.80 | NR1I2 (0.36) | PPARGPPARDGPR119NR1I2RET | |
| SCHEMBL1663632 | 0.80 | PDE10A (0.38) | PPARGPPARDGPR119NR1I2OGA | |
| SCHEMBL10327517 | 0.80 | TLR7 (0.38) | PPARGPPARDGPR119NR1I2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303026-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20140179709-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-06-26 | — | — | US | disclosed |
| US-8624025-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-01-07 | — | — | US | disclosed |
| US-20130005736-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-03 | — | — | US | disclosed |
| US-8217171-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20110212966-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-7951955-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-05-31 | — | — | US | disclosed |
| EP-2314582-A1 | Heterocyclic compounds as antiviral agents | Biota Scientific Management Pty Ltd (AU) | 2011-04-27 | — | — | EP | disclosed |
| US-7829705-B2 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2010-11-09 | — | — | US | disclosed |
| US-7829705-B2 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2010-11-09 | — | — | US | disclosed |
| US-7829705-B2 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2010-11-09 | — | — | US | disclosed |
| US-7579465-B2 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGMENT PTY. LTD. (AU) | 2009-08-25 | — | — | US | disclosed |
| US-20090030000-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2009-01-29 | — | — | US | disclosed |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-7166604-B2 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-01-23 | — | — | US | disclosed |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030000-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | PPARG 3081/4885PPARD 2637/4885GPR119 3013/4885 |
| US-20130005736-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | PPARG 3081/4885PPARD 2637/4885GPR119 3013/4885 |
| US-20110212966-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | PPARG 3081/4885PPARD 2637/4885GPR119 3013/4885 |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | EIF2AK2, IFNAR1, HAVCR2 | PPARG 3565/4885PPARD 2627/4885GPR119 4212/4885 |
| US-20140179709-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | PPARG 3081/4885PPARD 2637/4885GPR119 3013/4885 |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | RNASEH1, RPL35, SARS1 | PPARG 3402/4885PPARD 2866/4885GPR119 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.